Abstract:Introduction: Understanding the molecular underpinnings of vulvar squamous cell carcinoma (vSCC) has strong potential for clinical impact, given the unmet need for this rare cancer. vSCCs have two main etiologies, including human papillomavirus (HPV) infection or skin conditions such as lichen sclerosis. Clinically, few treatment options with limited efficacy are available for recurrent vSCCs and large whole transcriptome disease subtyping studies are limited due to the rarity of this cancer type. Here, we present a whole transcriptome subtyping study of 244 vSCC clinical samples with DNA genomic profiling. Furthermore, we compared vSCCs to other SCC disease subtypes (pan-SCC), including lung, esophageal, skin, urothelial, anal, and head and neck (HN). Our goal was to gain novel insights into the molecular landscape of vSCCs to inform new routes of therapy. Methods: Deidentified records of SCC patients were selected from the Tempus clinico-genomic database. The vSCC cohort was predominantly composed of, but not exclusively, naive or pre-treatment primary tissue. The pan-SCC cohort was limited to randomly sampled primary pre-treatment female samples with paired RNA and DNA sequencing. To perform vSCC subtyping, we used bulk RNA-seq and clustered the samples using FastPG-CC, an internally developed consensus-clustering extension of FastPG, a graph-based parallelized clustering tool. We next performed differential expression, pathway analysis, and cell type abundance estimation. Results: Unbiased gene expression clustering analysis identified three vSCCs clusters; an HPV+ cluster (HPV+, 32% of vSCC samples), HPV- cluster (HPV-, 33%), and an intermediate cluster which contained both HPV+ and HPV- samples (Mix, 35%). The HPV- cluster was enriched for TP53 and TERT promoter mutations, EMT and tumor microenvironment gene expression-derived pathways, and was most similar to HPV- oral HN tumors. The HPV+ cluster was enriched with PIK3CA mutations, cell cycle gene expression and was most similar to other HPV+ SCC samples, including cervical, anal, and HN. The Mix cluster was enriched for neutrophils, fatty acid metabolism and was most similar to skin SCC. Conclusions: We performed a multi-modal molecular subtyping analysis on a large cohort of vSCCs and identified three molecular subtypes, which enabled us to identify heterogeneity within vSCC, and observe that a subset of vSCCs share features with SCC tumor types for which there are emerging therapy options. Thus, this approach identifies a subset vSCCs that may be responsive to existing SCC therapeutics. Citation Format: Sara R. Selitsky, Tasha Thong, Kimberley Roche, Justin Guinney, Praveen Sethupathy, Catherine Igartua. Genomic characterization of vulvar squamous cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6454.

A pilot study of p53 immunohistochemistry in atypical squamous lesions, using a vulvar scoring system

Comparison of p53 immunohistochemical staining in differentiated vulvar intraepithelial neoplasia (dVIN) with that in inflammatory dermatoses and benign squamous lesions in the vulva

ROC-Analysis Derived Immunohistochemical P53 Cut-Off Scores as an Adjunct to Routine Histopathology for Better Diagnostic Compartmentalisation of Cervical Lesions

Relationship between p16/ki67 immunoscores and PAX1/ZNF582 methylation status in precancerous and cancerous cervical lesions in high-risk HPV-positive women

Identification of Potential Prognostic Biomarkers in Vulval Squamous Cell Carcinoma Based on Human Papillomavirus Infection Status-Analysis of GSE183454

Abnormal p53 Immunohistochemical Patterns Are Associated with Regional Lymph Node Metastasis in Oral Cavity Squamous Cell Carcinoma at Time of Surgery

PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva

Human papillomavirus and p53 status define three types of vulvar squamous cell carcinomas with distinct clinical, pathological, and prognostic features

p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies

Subclonal p53 immunostaining in the diagnosis of endometrial carcinoma molecular subtype

A study on H-score threshold for p16ink4a immunoperoxidase expression in squamous cell tumours of oral cavity

Prognostic value of an integrated human papilloma virus and immunoscore model to predict survival in vulva squamous cell carcinoma

Molecular events in the pathogenesis of vulvar squamous cell carcinoma

Immunohistochemistry and in situ hybridization for the diagnosis and classification of squamous lesions of the anogenital region

Unveiling a Dermatological Rarity: The Enigma of Vulvar Intraepithelial Neoplasia Grade III (HSIL) and the Role of p53 in Its Development

Diagnostic validity of p16, E-cadherin, cyclin D1, p53, and HPV E6/E7 mRNA in CIN 3-like squamous cell carcinoma of the cervix

Evaluation of Cervical High-Grade Squamous Intraepithelial Lesions-Correlated Markers as Triage Strategy for Colposcopy After Co-Testing

Utility of p53 in assessing margin status of resected squamous cell carcinoma

Abstract 6454: Genomic characterization of vulvar squamous cell carcinoma

A cocktail of p16INK4a and Ki-67, p16INK4a and minichromosome maintenance protein 2 as triage tests for human papillomavirus primary cervical cancer screening.